Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Data Byte: This router′s signal strength beat most competitors in our lab test (ZDNet EN) +++ NETGEAR Aktie +3,98%

REGENERON Aktie

 >REGENERON Aktienkurs 
641.4 EUR    +0.2%    (TradegateBSX)
Ask: 642.6 EUR / 100 Stück
Bid: 640.9 EUR / 100 Stück
Tagesumsatz: 61 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
REGENERON Aktie über LYNX handeln
>REGENERON Performance
1 Woche: +8,8%
1 Monat: +13,4%
3 Monate: +3,4%
6 Monate: -1,0%
1 Jahr: +28,1%
laufendes Jahr: -6,4%
>REGENERON Aktie
Name:  REGENERON PHARMACEUTICALS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US75886F1075 / 881535
Symbol/ Ticker:  RGO (Frankfurt) / REGN (NASDAQ)
Kürzel:  FRA:RGO, ETR:RGO, RGO:GR, NASDAQ:REGN
Index:  S&P500, Nasdaq100
Profil:  Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases across eye care, immunology, oncology, cardiovascular health, and inflammation. Its current portfolio in..
>Volltext..
Marktkapitalisierung:  63264.4 Mio. EUR
Unternehmenswert:  58051.82 Mio. EUR
Umsatz:  12946.32 Mio. EUR
EBITDA:  3803.13 Mio. EUR
Nettogewinn:  3838.36 Mio. EUR
Gewinn je Aktie:  36.91 EUR
Schulden:  2348.28 Mio. EUR
Liquide Mittel:  2577.71 Mio. EUR
Operativer Cashflow:  4349.72 Mio. EUR
Bargeldquote:  1.72
Umsatzwachstum:  -0.82%
Gewinnwachstum:  -7.94%
Dividende je Aktie:  3.12 EUR
Dividendenrendite:  0.52%
Dividendenschätzung:  0.53%
Div. Historie:  20.05.26 - 0.808306€
20.02.26 - 0.798906€
>weitere anzeigen...
Insiderhandel 1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 112.961 Euro.
Suchwörter:  REGENERON
Letzte Datenerhebung:  31.07.26
>REGENERON Kennzahlen
Aktien/ Unternehmen:
Aktien: 103.02 Mio. St.
Frei handelbar: 97.98%
Rückkaufquote: 3.36%
Mitarbeiter: 15410
Umsatz/Mitarb.: 0.81 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 16.93%
Bewertung:
KGV: 17.34
KGV lG: 14.18
KUV: 5.03
KBV: 2.38
PEG-Ratio: 3.8
EV/EBITDA: 15.26
Rentabilität:
Bruttomarge: 80.93%
Gewinnmarge: 29.65%
Operative Marge: 25.76%
Managementeffizenz:
Gesamtkaprendite: 11.28%
Eigenkaprendite: 14.55%
>REGENERON Peer Group
 
31.07.26 - 13:06
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation (GlobeNewswire EN)
 
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation...
31.07.26 - 03:12
Regeneron (REGN) Q2 2026 Earnings Call Transcript (Fool)
 
Revenue surged 17% as Dupixent and EYLEA HD posted record sales....
30.07.26 - 20:30
Regeneron expects EYLEA HD demand growth in the low to mid-teens in Q3–Q4 2026 amid prefilled syringe push (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.07.26 - 18:15
Regeneron (REGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
 
While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....
30.07.26 - 17:21
REGN Deadline Alert: SueWallSt Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026 (PR Newswire)
 
Important Notice Regarding Alleged Phase III Fianlimab-Libtayo Clinical Trial Risk Misrepresentations. The lawsuit alleges Regeneron investors overpaid while the Company characterized slowing event accrual as potentially favorable, even as the study allegedly faced heightened risk of......
30.07.26 - 16:30
Regeneron Pharmaceuticals declares $0.94 dividend (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.07.26 - 14:12
Regeneron übertrifft Erwartungen deutlich: Aktie legt vorbörslich zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
30.07.26 - 13:24
Regeneron Pharmaceuticals Inc Bottom Line Retreats In Q2 (AFX)
 
WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc (REGN) revealed a profit for second quarter that Drops, from the same period last yearThe company's earnings totaled $1.296 billion, or $12.23 ......
30.07.26 - 13:18
Regeneron rises after strong Q2 beat powered by high-dose Eylea (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.07.26 - 12:39
Regeneron Pharmaceuticals beats top-line and bottom-line estimates; updates FY26 outlook (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.07.26 - 12:33
Regeneron Reports Second Quarter 2026 Financial and Operating Results (GlobeNewswire EN)
 
TARRYTOWN, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2026 and provided a business update....
29.07.26 - 19:51
REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman (PR Newswire)
 
SAN FRANCISCO, July 29, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove......
29.07.26 - 16:33
Regeneron Pharmaceuticals Q2 2026 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
29.07.26 - 16:12
REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron Pharmaceuticals, Inc. Stockholders of Securities Class Action - Contact the Firm (PR Newswire)
 
Time-Sensitive: Allegations focus on Regeneron's statements about clinical differentiation in the Phase III Fianlimab-Libtayo Study and the last-minute protocol amendment used to force a trial readout. NEW YORK, July 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in......
28.07.26 - 17:30
Can These 5 Biotech Stocks Beat Wall Street′s Q2 Estimates? (Zacks)
 
Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results....
28.07.26 - 16:18
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial′s Protocol and Ultimate Failure - HBSS (PR Newswire)
 
SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove......
28.07.26 - 12:42
REGN Class Reminder: Regeneron Investors are Reminded of the Upcoming September 14 Deadline in the Filed Securities Fraud Class Action to Recover Losses (PR Newswire)
 
A securities fraud class action lawsuit has been filed on behalf of Regeneron investors after its stock plummeted almost 10% because Regeneron allegedly misled investors regarding the success of its Phase III Fianlimab-Libtayo clinical trial. NEW YORK, July 28, 2026 /PRNewswire/ --......
27.07.26 - 23:39
Regeneron Pharmaceuticals (NASDAQ: REGN) Investors Who Suffered Losses May Be Eligible to Participate in the Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses (PR Newswire)
 
Lead Plaintiff Deadline: September 14, 2026 SAN DIEGO, July 27, 2026 /PRNewswire/ -- Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between......
27.07.26 - 15:36
INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit (PR Newswire)
 
SAN FRANCISCO, July 27, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove......
24.07.26 - 19:42
The Scientist With 1,000 Patents Fueling a Drug Powerhouse (WSJ EN)
 
At Regeneron, George Yancopoulos is the rare scientist and executive who drives growth with discoveries instead of acquisitions....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ein Bauer, der den ganzen Wald schlägert, ist auf dem Holzweg. - Dr. Fritz P. Rinnhofer
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!